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Abstract
 
Cell surface expression of major histocompatibility complex class II (MHCII) molecules is in-
creased during the maturation of dendritic cells (DCs). This enhances their ability to present
 
antigen and activate naive CD4
 

 
 T cells. In contrast to increased cell surface MHCII expres-
sion, de novo biosynthesis of MHCII mRNA is turned off during DC maturation. We show
here that this is due to a remarkably rapid reduction in the synthesis of class II transactivator
(CIITA) mRNA and protein. This reduction in CIITA expression occurs in human mono-
cyte-derived DCs and mouse bone marrow–derived DCs, and is triggered by a variety of dif-
 
ferent maturation stimuli, including lipopolysaccharide, tumor necrosis factor 
 

 
, CD40 ligand,
 
interferon 
 

 
, and infection with 
 
Salmonella typhimurium
 
 or Sendai virus. It is also observed in
vivo in splenic DCs in acute myelin oligodendrocyte glycoprotein induced experimental au-
toimmune encephalitis. The arrest in CIITA expression is the result of a transcriptional inacti-
vation of the 
 
MHC2TA
 
 gene. This is mediated by a global repression mechanism implicating
histone deacetylation over a large domain spanning the entire 
 
MHC2TA
 
 regulatory region.
Key words: MHC class II • class II transactivator • experimental autoimmune encephalitis • 
bare lymphocyte syndrome • histone deacetylation
 
Introduction
 
Dendritic cells (DCs)
 
*
 
 are specialized for the initiation of
primary immune responses because they are the most po-
tent APCs for the activation of naive T cells. Moreover,
they provide a key link between the innate and adaptive
immune systems (1, 2). Two distinct stages of DC differen-
tiation are recognized. Immature DCs are found in the pe-
riphery at strategically important sites where they act as sur-
veillance cells. These immature DCs are characterized by a
high capacity for antigen uptake but are rather poor at acti-
 
vating T cells. Inflammatory stimuli and exposure to infec-
tious agents triggers an irreversible differentiation into ma-
ture DCs. During maturation, endocytotic activity is lost
(3), and internalized antigens are processed and presented by
MHC molecules at the cell surface (4, 5) cytokines (IL-12)
are released (6, 7), costimulatory molecules (CD80, CD86,
CD40) are upregulated (3, 8), and the expression of specific
chemokine receptors (CCR7) is induced (9). These
changes ensure that the DCs migrate to the T cell areas of
the secondary lymphoid organs and are efficient at activat-
ing antigen-specific T lymphocytes.
Changes in the intracellular localization and cell surface
expression of MHC class II (MHCII) molecules are inti-
mately associated with the function and maturation of DCs
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(4, 5, 10, 11). In immature DCs, MHCII molecules are
largely retained in intracellular compartments. Upon matu-
ration, MHCII–peptide complexes are assembled and
transported to the cell surface. Although these changes at
the level of MHCII protein distribution have been ad-
dressed in considerable detail, relatively little is known
about the mechanisms that regulate alterations in the actual
de novo biosynthesis of MHCII molecules during DC mat-
uration (4, 5).
MHCII expression is regulated primarily at the level of
transcription (12–16). Several key regulatory factors con-
trolling the transcription of MHCII genes have been iden-
tified thanks to the elucidation of the molecular defects
underlying MHCII deficiency, a severe hereditary immu-
nodeficiency syndrome resulting from the lack of MHCII
expression (17–21). One of the factors identified by these
studies—the MHCII transactivator CIITA—is a tran-
scriptional coactivator that functions as a key regulatory
factor for MHCII expression (22, 23). The expression pat-
tern of CIITA dictates most qualitative and quantitative as-
pects of MHCII gene expression. The cell type specificity,
induction, and level of MHCII expression are in the ma-
jority of situations determined by the expression of CIITA
(24–27). The gene encoding CIITA (
 
MHC2TA
 
) is con-
trolled by three distinct and independent promoters re-
ferred to as pI, pIII, and pIV. These promoters are spread
out over a large (
 

 
12 kb) regulatory region and exhibit dif-
ferent cell type specificities (28). pIII is used mainly in B
cells (28, 29). IFN-
 

 
–induced CIITA expression is medi-
ated by pIV (28, 30–32). Expression of the 
 
MHC2TA
 
 gene
in DCs has previously been shown to be controlled prima-
rily by pI, and to a lesser degree by pIII (28).
In the work reported here we have studied the mecha-
nisms controlling de novo MHCII biosynthesis during DC
maturation induced by stimuli such as LPS, TNF-
 

 
, CD40
ligand (CD40L), IFN-
 

 
, infection with bacteria or viruses,
and the induction of experimental autoimmune encephali-
tis (EAE). Although cell surface MHCII expression is in-
creased, de novo synthesis of MHC mRNA is actually re-
duced. We show that this is due to a rapid downregulation
in the abundance of CIITA mRNA and protein. This loss
of CIITA expression is the consequence of a simultaneous
transcriptional shut down of promoters pI and pIII of the
 
MHC2TA
 
 gene. The fact that these promoters are situated
far apart, and are regulated independently of each other in
other cell types, implies that a global silencing mechanism
affecting a large region of the 
 
MHC2TA
 
 gene is likely to
be involved. In accordance with this, we show that his-
tones along the entire regulatory region of the 
 
MHC2TA
 
gene are deacetylated during DC maturation, indicating
that chromatin remodeling over a large domain is involved
in the transcriptional silencing mechanism.
 
Materials and Methods
 
DCs.
 
Human monocyte-derived DCs were prepared essen-
tially as described (33). Briefly, PBMCs were prepared from buffy
 
coat fractions (Blood Transfusion Centre) by isolation over Ficoll-
Paque (Amersham Pharmacia Biotech). Monocytes were obtained
by adhesion in RPMI 2% FCS at 37
 

 
C for 1 h and depleted of
CD19
 

 
 cells using magnetic beads (Dynal). The monocytes, 
 

 
90%
pure as assessed by flow cytometry, were cultured in IMDM 10%
FCS supplemented with 2-mercaptoethanol (50 
 

 
M), GM-CSF
(600 U/ml, Leukomax; Essex Chemie AG), and IL-4 (750 U/ml;
R&D Systems). Every 2 d, half of the medium was replaced by
fresh medium containing a twofold concentration of cytokines.
After 6 d, the cells exhibited an immature DC phenotype
(CD14
 

 
CD1a
 

 
MHCII
 
low
 
CD86
 
low
 
CD40
 
low
 
CD80
 

 
CD83
 

 
). Un-
less indicated otherwise, maturation was induced by stimulating
the immature DCs with LPS for 24 h. Mature DCs can be identi-
fied by high levels of surface MHCII, costimulatory molecules
(CD86, CD80, and CD40), and the DC-restricted marker CD83.
To induce maturation, immature DCs were plated at 0.5–1 
 
	
 
10
 
6
 
 cells/ml in IMDM 10% FCS supplemented with either LPS
(from 
 
Salmonella abortus equi
 
, 10 ng/ml; Sigma-Aldrich), TNF-
 

 
(75 ng/ml; R&D systems), IFN-
 

 
 (1,000 U/ml, provided by C.
Weissmann, University of Zürich, Zürich, Switzerland), or IFN-
 

 
(1,000 U/ml; Life Technologies). For stimulation with CD40L,
immature DCs were cocultured at a ratio of 1:5 with CD40L-
expressing J558L cells (a gift from E. Padovan, University Hospital
of Basel, Basel, Switzerland). For infection with 
 
Salmonella ty-
phimurium
 
 (strain 14028 phoQ24), 5 
 
	
 
 10
 
6
 
 cfu were added per 2.5 
 
	
 
10
 
5
 
 immature DCs and the mixture was incubated for 30 min at
37
 

 
C. Extracellular bacteria were then killed by the addition of
Gentamycin (50 
 

 
g/ml; Sigma-Aldrich). For infection with Sen-
dai (strain M, SeV
 
M
 
), the virus was added to immature DCs at a
multiplicity of infection of 20. Trichostatin A (TSA; Sigma-Aldrich)
was coadministered with LPS at 100 ng/ml.
Mouse bone marrow–derived DCs (BMDCs) were generated
according to M.B. Lutz et al. (34). Bone marrow cells were iso-
lated from femurs and tibiae of 8-wk-old female C57BL/6 mice
(RCC) and cultivated in RPMI 10% FCS. mGM-CSF (200 U/ml;
PeproTech) was added at day 0, 3, 6, 8, and 10. Cells were then
collected and induced to maturate with LPS (10 
 

 
g/ml) for 24 h.
Maturation was monitored by FACS
 
®
 
 analysis of surface expres-
sion of MHCII, CD86, CD83, and CD40 and by quantification
of CCR1 and CCR7 mRNA expression.
 
Cell Lines.
 
The Burkitt’s lymphoma cell line Raji and the
CIITA-deficient cell line RJ2.2.5 were grown in RPMI 10%
FCS. RJ2.2.5 was transfected with an episomal expression vec-
tor containing a CIITA type I cDNA under the control of the
SR
 

 
 promoter. Transfected cells were selected with hygromy-
cin for 10 d and checked for cell surface MHCII expression by
FACS
 
®
 
.
 
Cytofluorometry.
 
DCs were blocked with mouse IgG (2 mg/
ml) before staining. Anti–human antibodies used were FITC-con-
jugated anti–HLA-DR (clone G46–6; BD PharMingen), anti-
CD80 (clone BB1; BD PharMingen), and anti-CD40 (clone 5C3;
BD PharMingen); PE-conjugated anti-CD1a (clone BL6; Immu-
notech), anti-CD83 (clone HB15a; Immunotech), and anti-CD86
(clone IT2.2; BD PharMingen); and biotinylated anti-CD14
(clone UCHM1; Ancell) followed by allophycocyanin-conjugated
streptavidin (BD PharMingen). Dead cells were excluded by load-
ing with 7-aminoactinomycin D (Sigma-Aldrich). Staining with
isotype-matched antibodies was performed in parallel.
 
EAE.
 
7-wk-old C57BL/6 mice (RCC) were immunized as
described (35) with myelin oligodendrocyte glycoprotein (MOG)
peptide 35–55 in CFA and treated with pertussis toxin intraperi-
toneally. On day 2 the animals were again treated with pertussis
toxin and on day 7 the animals were boosted with MOG peptide.
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Animals with acute EAE (scores 2–3) were killed on day 20 or
21. For isolation of ex vivo DCs, eight spleens were pooled, low
density cells were enriched over an OptiPrep™ density gradient
(Nycomed Pharma), and CD11c
 

 
MHCII
 
high
 
 DCs were sorted by
FACS
 
®
 
. Total mRNA was isolated from these cells or from total
spleen and analyzed by real time PCR.
 
RNA Preparation.
 
Total RNA was prepared with Trizol (Life
Technologies) according to the manufacturer’s instructions.
 
RNase Protection Assay.
 
RNase protection assays (RPAs)
were performed with total RNA as described (36). The RPA
probes for mRNAs of GAPDH, DRA, total CIITA, and the spe-
cific forms of CIITA have been described previously (27, 28, 35,
37). The probes for human CIITA mRNA are depicted schemat-
ically in Fig. 3 A. Results were quantified by PhosphorImager
analysis using the ImageQuant program.
 
Real Time PCR.
 
cDNA was synthesized from total RNA us-
ing random hexamers and Superscript II reverse transcriptase
(Life Technologies). cDNA from 40 ng of total RNA (supple-
mented with 0.8 
 

 
g yeast tRNA) was used per PCR reaction.
Real time PCR was performed with the TaqMan sequence de-
tection system (Applied Biosystems). The PrimerExpress software
was used to design the primers and TaqMan probes for detection
of human mRNAs and nonspliced nascent transcripts (see Fig. 3
A). The sequences of the primers and probes are as follows. Total
CIITA mRNA: forward 5
 


 
-CCTGCTGTTCGGGACCTAAA-
3
 


 
, reverse 5
 


 
-GGATCCGCACCAGTTTGG-3
 


 
, probe 5
 


 
-
AGGGCCCAGCGCAAACTCCAGT-3
 


 
. Spliced type I CIITA
mRNA: forward 5
 


 
-CTAGAGAAAGGAGACCTGGATTTG-3
 


 
,
reverse 5
 


 
-TCATAGAAGTGGTAGAGGCACAGG-3
 


 
, probe
5
 


 
-CTGGAGCTTCTTAACAGCGATGCTGACC-3
 


 
. Spliced
type III CIITA mRNA: forward 5
 


 
-TGGGATTCCTACA-
CAATGCGT-3
 


 
, reverse 5
 


 
-GGGTCAGCATCGCTGTTAA-
GA-3
 


 
, probe 5
 


 
-CAGAGCCCCAAGGCAGCTCACAGT-3
 


 
.
Nonspliced type I CIITA transcripts: forward 5
 


 
-GCCCCGGC-
CACAGTG-3
 


 
, reverse 5
 


 
-TCCCATTGACTTCCCTTTC-
AGA-3
 


 
, probe 5
 


 
-TGATTAAAAGTGATGCCAACTTAC-
CACCATGG-3
 


 
. Nonspliced type III CIITA transcripts: forward
5
 


 
-TGCTGGGTCCTACCTGTCAGA-3
 


 
, reverse 5
 


 
-CAG-
GACCAGCTGAGACTGCAC-3
 


 
, probe 5
 


 
-CTTTCCCGGC-
CTTTTTACCTTGGGG-3
 


 
. HLA-DRA mRNA: forward
5
 


 
-GCCAACCTGGAAATCATGACA-3
 


 
, reverse 5
 


 
-AGGGCT-
GTTCGTGAGCACA-3
 


 
, probe 5
 


 
-CAACTATACTCCGAT-
CACCAATGTACCTCCAGAG-3
 


 
. A primer-probe combina-
tion for GAPDH mRNA was used as internal control (Applied
Biosystems). The primers and probe for mouse mRNAs are as
follows. mCIITA I: forward 5
 


 
-CAGGGACCATGGAGAC-
CATAGT-3
 


 
, reverse 5
 


 
-CAGGTAGCTGCCCTCTGGAG-3
 


 
and probe 5
 


 
-TGTGTGCCACCATGGATCTGGGA-3
 


 
. mCI-
ITA III: forward 5
-GGTTCCTGGCCCTTCTGG-3
, reverse
5
-ATCCATGGTGGCACACAGACT-3
, and probe 5
-TCT-
TACCTGCCGGAGTTGCAAGACCA-3
. mCIITA IV: forward
5
-CAGCACTCAGAAGCAACGGG-3
, reverse 5
-ATCCA-
TGGTGGCACACAGACT-3
, and probe 5
-CACAGCCAC-
AGCCGCGACCA-3
. mCCR7: forward 5
-ACAGCCCCCA-
GAGCACC-3
, reverse 5
-GAGCCACCACCAGCACGT-3
, and
probe 5
-TTTCCTGGGTTTCCCTGGGTCCA-3
. An mCCR1
primer-probe combination was purchased from Applied Biosys-
tems. As endogenous control, a set of primers and probe specific
for mouse 18S ribosomal RNA (Applied Biosystems) was used.
Samples were quantified using relative standard curves for each
amplification. All results are normalized with respect to the inter-
nal control, and are expressed relative to the levels found in im-
mature DCs.
Measurement of CIITA mRNA Stability. Immature DCs or
DCs stimulated with LPS for 2.5 h were supplemented with 50
M 5,6-dichloro-1--ribofuranosyl benzamidazole (DRB;
Sigma-Aldrich) for 0, 1, 2, 3, and 4 h. Total RNA was then pre-
pared and the remaining CIITA mRNA was quantified by real
time PCR.
Isolation of Nascent RNAs. Nascent transcripts and free nu-
clear RNAs were isolated from 10 	 106 cells as described (28,
38). Nascent transcripts and free nuclear RNAs were treated with
RNase-free DNaseI (Roche). Nascent transcripts and free nu-
clear RNAs, from 1.2 	 105 and 3 	 104 cells respectively, were
analyzed by real time PCR.
In Vivo Genomic Footprinting. In vivo genomic footprinting
was done by ligation-mediated PCR (LM-PCR) as described
(39) using Vent DNA polymerase (New England Biolabs, Inc.)
for all steps. pI was analyzed between bp 80 and 164 using
primer set A for the lower strand (A1, 5
-ATTGGCTCCAACA-
GAAGGCTG-3
; A2, 5
-CAGAAGGCTGTGGGCTTCTC-
TG-3
; A3, 5
-TGGGCTTCTCTGGCACATGCACCTG-3
)
and primer set B for the upper strand (B1, 5
-CTGGCCAGT-
GCCTGGAATC-3
; B2, 5
-GTGCCTGGAATCTCCGCT-
CAC-3
; B3, 5
-TCCGCTCACCCAGCATGCAGCATC-3
).
pIII was analyzed between bp 20 to 220 using primer set C
for the upper strand (C1, 5
-AGAAGCACACAGCCTCAT-
CACTA-3
; C2, 5
-CACTAGCCTCATCACTAACCAGT-
CA-3
; C3, 5
-TAACCAGTCACCAGTTGGGAGCCCG-3
).
Immunoprecipitation and Immunoblotting. Antibodies specific for
the NH2 terminus (anti–CIITA-N) or COOH terminus (anti–
CIITA-C) of CIITA have been described (40). Anti–CIITA-C
antibodies were covalently coupled with dimethyl pimelinediimi-
date (DMP; Fluka) to protein-A Sepharose beads according to
standard protocols (41). Preparation of protein extracts and im-
munoprecipitation using 5 	 106 cells per sample were done as
described (40). SDS-PAGE, immunoblotting with anti–CIITA-N
antibodies, and quantification were performed according to stan-
dard protocols.
Chromatin Immunoprecipitation and Quantification. Chroma-
tin immunoprecipitations were done as described previously (40).
Antibodies specific for acetylated histones H3 and H4 were pur-
chased from Upstate Biotechnology. The immunoprecipitated
promoter fragments were amplified by PCR and analyzed on 4%
agarose gels or quantified with the SYBR green real time PCR
method (Applied Biosystems). The primers for each amplicon
were as follows. A, 5
-CCCCAGCTGAGAGATGGTAATC-3

and 5
-GCACAAAACAGAGGATTTGCATAG-3
; B, 5
-AAA-
AGCCAATATCCATCCGTTC-3
 and 5
-GCATCCAAAAC-
ATGAAGTGAAAAC-3
; C, 5
-CCAGGCTGCTTGCGAAC-3

and 5
-TGCATTTCAGAAGGAGATGGAAT-3
; D, 5
-TGG-
GGCCCCAGACAATATC-3
 and 5
-GCCCATGTGCCAGT-
TCAAC-3
; E, 5
-TCCTGGCTGGGTACCACTG-3
 and
5
-CTCTGAGCAGAGCAAGTGACATC-3
; F, 5
-AGAAACA-
GAAATCTGACCGCTTG-3
 and 5
-TCATCACTAACCA-
GTCACCAGTTG-3
; G, 5
-CCACTGTGAGGAACCGAC-
TG-3
 and 5
-TGGAGCAACCAAGCACCTAC-3
; GAPDH,
5
-CCCGGCTACTAGCGGTTTTAC-3
 and 5
-CTGCGGG-
CTCAATTTATAGAAAC-3
.
Results
Maturation of DC Is Accompanied by a Reduction in MHCII
mRNA Expression. To gain insight into the regulation of
MHCII expression during DC maturation, we analyzed
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transcription of the HLA-DRA gene in immature and ma-
ture DCs. Immature DCs were generated from human pe-
ripheral blood monocytes by incubation with GM-CSF
and IL-4 for 6 d, and were induced to mature with LPS.
The CD1aCD14 phenotype of the cells was determined
by FACS® analysis and the absence of B lymphocytes was
confirmed by the lack of CD19 cells (data not shown).
Upregulation of cell surface CD83, CD86, CD80, and
CD40 was examined to control for maturation (Fig. 1, A
and B). As described previously (33), the mature DCs are
characterized by a markedly increased level of cell surface
MHCII expression (Fig. 1, A and B).
To study changes in steady-state MHCII mRNA levels
we first performed RPAs with total RNA from immature
and LPS-stimulated DCs (Fig. 1 C). Immature DCs and
DCs treated with LPS for 3 h expressed high levels of DRA
mRNA. However, after 24 h of stimulation a marked re-
duction in DRA mRNA is evident. DRA mRNA levels
were next quantified using a real time PCR approach (Fig.
1 D). A transient 40% increase in DRA mRNA is observed
at early time points (3 h). However, after 24 and 48 h of
stimulation with LPS the level of DRA mRNA is reduced
to 35 and 23% of the initial level. Thus, although cell sur-
face MHCII expression is increased, steady-state MHCII
Figure 1. Downregulation of MHCII mRNA expression during the
maturation of human monocyte-derived DCs. (A) Cell surface expression
of CD1a, HLA-DR, CD83, CD80, CD86, and CD40 was examined by
two-color FACS® analysis of immature DCs and DCs matured with LPS
for 24 h. (B) Histogram plots for cell surface expression of HLA-DR,
CD83, CD86, CD80, and CD40 on immature and mature DCs. The
data in panels A and B represent two independent experiments. (C)
Steady-state levels of HLA-DRA mRNA were studied by RPA in imma-
ture DCs and DCs stimulated for 3 and 24 h with LPS. GAPDH mRNA
was measured as an internal control. (D) HLA-DRA mRNA was quanti-
fied by real time PCR in immature DCs and DCs stimulated with LPS
for 3, 24, and 48 h. Values for DRA mRNA are normalized with respect
to GAPDH mRNA, and are provided as the percentage of the level
found in immature DCs. The mean and SEM of three independent ex-
periments are shown. rel., relative.
Figure 2. Downregulation of CIITA protein expression during matu-
ration of DCs. (A) CIITA is required for expression of MHCII genes in
DCs. MHCII cell surface expression on BMDCs from wild-type (WT)
and CIITA knockout (KO) mice. The cells were either left untreated or
stimulated with LPS for 24 h. (B) The three types of CIITA mRNA
(types I, III, and IV) encode three different protein isoforms (121, 124,
and 132 kD). These proteins differ only at their N-terminal end. White
bars represent the CIITA mRNAs and black bars represent the proteins
encoded by these mRNAs. The boundary between the alternative first
exons and the shared downstream exons is indicated by a vertical line.
The positions of translation initiation codons are indicated. The scheme is
not drawn to scale. (C) CIITA proteins were immunoprecipitated with
the anti–CIITA-C antibody from extracts derived from immature (lane 2)
and mature (lane 3) DCs, and were revealed by immunoblotting using the
anti–CIITA-N antibody. Control immunoprecipitations were done with
extracts from Raji cells and a transfectant expressing CIITA type I
mRNA. Raji cells express only the type III CIITA mRNA and thus syn-
thesize high levels of the 124-kD isoform and a lower level of the 121-kD
isoform (lane 4). The transfectant expresses only type I CIITA mRNA
and thus synthesizes high levels of the 132-kD isoform and a low amount
of the 121-kD isoform (lane 5). An immunoprecipitation performed with
preimmune serum (PI) and the extract from immature DCs was used as
negative control (lane 1). A contaminant that is immunoprecipitated non-
specifically from the DC extracts is indicated (unsp.).
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mRNA levels are reduced four- to fivefold. This finding is
consistent with earlier experiments demonstrating that DC
maturation is accompanied by a decrease in de novo syn-
thesis of MHCII proteins (4, 42).
CIITA Expression during DC Maturation. Multiple lines
of evidence indicate that expression of the transactivator
CIITA is a key requirement for expression of MHCII
genes in a wide variety of cell types, including DCs. Epi-
dermal DCs in a patient suffering from MHCII deficiency
due to a mutation in the CIITA gene were found to be
completely devoid of MHCII expression (43). In addition,
fresh DCs from the spleen of CIITA knockout mice were
found to be negative for MHCII expression (44, 45).
MHCII expression is also strongly reduced in DCs isolated
from lymph nodes of CIITA-deficient mice, although a re-
sidual (20% of normal) expression level is retained in these
cells (46). Here we provide further evidence that cell sur-
face MHCII is strongly reduced (100-fold) on BMDCs
from CIITA knockout mice, both in the presence and ab-
sence of LPS (Fig. 2 A). We therefore investigated whether
the decrease in MHCII mRNA observed in mature DCs
could be accounted for by a reduction in the level of CIITA
protein. CIITA is a rare protein that is not abundant
enough in DCs to be detected directly by immunoblotting.
We therefore performed immunoprecipitations followed
by immunoblotting using two different anti-CIITA anti-
bodies to increase sensitivity and specificity (Fig. 2 C).
Three different CIITA protein isoforms can be synthesized
from the three types of CIITA mRNA derived from pro-
moters pI, pIII, and pIV (Fig. 2 B). These three CIITA iso-
forms have predicted molecular weights of 121, 124, and
132 kD. The shortest 121-kD isoform can be synthesized
from all three types of CIITA mRNA by initiation at the
AUG codon situated in the shared second exon. The 132-
kD and the 124-kD isoforms are produced by initiation at
the upstream AUG codons present in the specific first ex-
ons of the type I and type III CIITA mRNAs. All three
CIITA isoforms are detected in immature DCs (Fig. 2 C,
lane 2). After maturation there is an eightfold reduction in
CIITA protein. The remaining CIITA is almost exclusively
(95%) of the 121-kD isoform.
CIITA mRNA Reduction during DC Maturation. We next
examined the steady-state levels of the different types of
CIITA mRNA in immature and LPS-stimulated DCs.
Two different quantitative approaches, RPA and real time
PCR, were used. The probes and primers used for RPA
and real time PCR are depicted schematically in Fig. 3 A.
Types I and III CIITA mRNAs are abundant in immature
DCs (Fig. 3 B). This is consistent with the finding that
these cells express 132 and 124 kD CIITA proteins (see
Fig. 2). On the other hand, type IV CIITA mRNA is
scarcely detectable (Fig. 3 B). This implies that the 121-kD
isoform observed in the immature DCs is likely to be de-
rived from initiation at the translation initiation codon situ-
ated in the second exon of the type I and type III mRNAs
(see Fig. 2). The CIITA mRNA profile observed in the
immature DCs contrasts with the one observed for the
monocytes from which they are derived. The latter express
much lower levels of CIITA mRNA and essentially only
type III is detected (Fig. 3 B). This is consistent with previ-
ous work indicating that the type I mRNA is specific for
DCs while the type III mRNA is detected in DCs as well
as in other cell types (28).
After LPS-induced maturation, a rapid reduction in CIITA
mRNA is observed. This is evident both when using RPA
and real time PCR to measure the CIITA mRNA levels
(Fig. 3, B–D). Expression of CIITA mRNA is reduced
within a matter of hours. After 3 h of stimulation the level
of CIITA mRNA is already reduced by 80–90% and is
even lower after 24 h. Interestingly, this strong reduction
concerns both type I and type III CIITA mRNA even
though pI and pIII have not been shown previously to be
regulated coordinately. The reduction in CIITA mRNA
expression is considerably more rapid than the reduction
observed for MHCII mRNA (compare Figs. 1 and 3). This
difference in kinetics is due, at least in part, to the fact that
the half life of MHCII mRNA in DCs is very long (over
24 h; data not shown) with respect to the half life of CIITA
mRNA (1 h; see Fig. 6).
To delineate more precisely the kinetics and extent of
the decrease in CIITA mRNA during LPS-induced matu-
ration we performed detailed time course experiments us-
ing real time PCR to measure mRNA levels (Fig. 3 E).
Expression levels of both type I and type III CIITA mRNAs
start to fall significantly within the first hour and basal levels
are reached after 3–5 h. This loss in expression is essentially
complete for CIITA type I mRNA, whereas the minimum
attained by type III represents only 20% of the initial
level.
To determine whether our findings with human mono-
cyte-derived DCs could be extended to other DC prepara-
tions we examined CIITA expression during the matura-
tion of mouse BMDCs. The predominant form of CIITA
mRNA in mouse BMDCs is of type I (data not shown; ref-
erence 35). The type III and type IV mRNAs are expressed
at lower levels. After exposure to LPS, the mature BMDCs
express high levels of cell surface MHCII, CD86, CD80,
and CD40 (data not shown; reference 47). Furthermore,
maturation of DCs is associated with the upregulation of
CCR7 and reduction of CCR1 mRNA expression (48;
Fig. 4 A). In these LPS-matured BMDCs, the expression of
all three types of CIITA mRNA is reduced (Fig. 4 B). As
observed in human monocyte-derived DCs, the reduction
is strongest for type I CIITA mRNA. The decrease is less
marked for types III and IV. However, final absolute levels
of the three forms are likely to be similar because types III
and IV are expressed at lower levels before maturation.
Extinction of CIITA Expression Is a General Consequence of
DC Maturation. To determine whether the decrease in
CIITA expression was a specific response to stimulation
with LPS or a more general consequence of DC matura-
tion, we measured CIITA mRNA levels in human mono-
cyte-derived DCs exposed to a variety of different matura-
tion signals. These included stimulation with LPS, TNF-,
CD40L, or IFN-, and infection with S. typhimurium or
Sendai (SeVM). Real time PCR analysis revealed that all
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stimuli elicited a striking downregulation of total CIITA
mRNA expression (Fig. 5). As observed for LPS, CIITA
mRNA type I was affected more strongly than type III by
the other maturation stimuli (data not shown). S. typhimu-
rium, LPS, and IFN- provoked a downregulation of total
CIITA mRNA to 20–30% of initial levels within 4 h,
whereas the reduction induced by SeVM, TNF-, and
CD40 liter reached these levels after only 24 h. Despite this
variability in kinetics, we can conclude that the decrease in
CIITA expression is an integral feature of DC maturation
rather than a response restricted to stimulation with LPS.
Further confirmation of the reduction in CIITA mRNA
expression in DCs was obtained in an in vivo system (35).
To study changes in CIITA mRNA levels in DCs in an in-
flammatory disease, we examined expression of the DC-
specific type I CIITA mRNA in the spleen of mice with
acute EAE. In mice with MOG-induced EAE we found a
marked decrease in CIITA type I mRNA in total spleen
(Fig. 4 C), suggesting that a decrease in CIITA expression
also occurs in DCs in vivo. To confirm that this is indeed
the case we compared CIITA mRNA levels in purified
DCs isolated from the spleen of control mice and mice
with EAE (Fig. 4 D). In the latter, the expression of all
three forms of CIITA mRNA is strongly reduced. A strong
downregulation of CIITA expression is thus observed in
mouse DCs in vivo during an inflammatory process.
Figure 3. A strong and rapid
downregulation of CIITA
mRNA expression is induced
during maturation of DCs. (A)
Strategy for detecting the differ-
ent spliced and unspliced types of
CIITA mRNA by RPA and real
time PCR. The structure of the
MHC2TA gene (top) and the
different CIITA mRNAs (bot-
tom) are indicated schemati-
cally. Dashed lines indicate the
pattern of splicing. White boxes
represent exons; thin black lines
represent introns. RPA probes
specific for total CIITA mRNA
and CIITA mRNAs of types I,
III, and IV are indicated below.
For each probe the sizes in nu-
cleotides (nu) are indicated for
the nondigested probe, the pro-
tected fragment specific for the
corresponding type of CIITA
mRNA (specific), and the pro-
tected fragment corresponding
to the other types of CIITA
mRNA (non-I, non-III, non-
IV). Sets of primers (arrows) and
probes (black rectangles) used in
real time PCR to quantify total
CIITA mRNA, and spliced and
unspliced CIITA transcripts of
type I and type III are shown in
the middle. (B) Quantification of
the different types of CIITA
mRNA present in monocytes,
immature, and mature DCs as
measured by RPA. The results
are standardized with respect to
endogenous GAPDH mRNA.
(C) Expression of type I and type
III CIITA mRNA was analyzed
by RPA in immature DCs (lanes
1 and 4) and DCs stimulated
with LPS for 3 h (lanes 2 and 5)
and 24 h (lanes 3 and 6). A probe
specific for total CIITA was in-
cluded in addition to the probes
specific for CIITA type I or type
III. A probe for GAPDH
mRNA was included as internal control. (D) Results form the RPA analysis (C) were quantified by PhosphorImager and compared with data obtained
by real time PCR on the same RNAs. The values are normalized with respect to GAPDH mRNA and are given as the percent relative to the levels
found in immature DCs. (E) The kinetics of the reduction in type I, type III, and total CIITA mRNA was determined by real time PCR on RNA pre-
pared from DCs stimulated with LPS for various periods of time. The values are normalized and presented as in D.
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In addition to known maturation stimuli, we also exam-
ined the effect on DCs of IFN-, a stimulus known to
modulate CIITA and MHCII expression in many cell
types. Treatment of immature DCs with IFN- does not
lead to maturation (data not shown) and does thus not re-
sult in a reduction of MHCII and CIITA mRNA expres-
sion (Fig. 5 B). If anything, a slight increase in MHCII and
total CIITA mRNA expression is observed (Fig. 5 B). This
IFN- induced increase is very mild compared with the in-
duction seen in other cell types, probably because the basal
level in DCs is already very high.
We also examined the effect of including IFN- during
Figure 5. Downregulation of CIITA expression in DCs exposed to
various different stimuli. (A) Immature DCs were exposed to the indi-
cated maturation stimuli for 4 and 24 h and total CIITA mRNA was
quantified. (B) DRA and total CIITA mRNA levels were quantified in
immature DCs stimulated with IFN- for 24 h. (C) DRA and total CIITA
mRNA levels were quantified in immature DCs stimulated with LPS for
24 h in the presence or absence of IFN-. (D) CIITA type I, type III, and
type IV mRNA levels were analyzed in the samples from panel C. Real
time PCR was performed for the quantification of mRNAs in all panels.
The values are normalized and represented as in Fig. 3 D. For each stim-
ulation (A–C), the mean and SEM of two to four independent experi-
ments are shown.
Figure 4. The reduction in CIITA mRNA expression is also observed
in mouse DCs. (A) Mouse BMDCs were induced to maturate by stimula-
tion with LPS for 24 h. CCR1 and CCR7 mRNA expression levels were
determined by real time PCR to control for DC maturation. (B) The ex-
pression levels of the three types of CIITA mRNA were compared in the
immature and mature BMDCs using real time PCR. The results are nor-
malized with respect to 18S ribosomal RNA and are given as the percent
relative to the levels found in immature BMDCs. The mean and SEM of
three independent experiments are shown. (C) CIITA type I mRNA ex-
pression in total spleen was determined by RPA for control mice and
mice with MOG-induced EAE. The values are normalized with respect
to expression levels in naive animals. Four mice from three independent
experiments are shown (#1 to #4). Types III and IV CIITA mRNAs
were not considered here because they are expressed at high levels in B
cells and IFN- induced cells, which would obscure the analysis. (D)
Splenic DCs were purified from mice with MOG-induced EAE and total
RNA was isolated. CIITA type I, type III, and type IV mRNAs were
quantified by real time PCR. The results were normalized with respect to
18S rRNA. Expression levels in naive animals were set at 100%.
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DC maturation induced by LPS. The presence of IFN-
partially prevented the decrease in MHCII and total CIITA
mRNA during DC maturation (Fig. 5 C). This is not due
to an inhibition by IFN- of the decrease in types I and III
CIITA mRNA (Fig. 5 D). Instead, it results from the fact
that the decrease in types I and III mRNA is compensated
for partially by activation of CIITA type IV mRNA ex-
pression (Fig. 5 D).
The Decrease in CIITA mRNA Expression Is Due to an Ar-
rest in Transcription. To determine whether the decrease
in steady-state levels of CIITA mRNA could be due to
mRNA destabilization, we compared the stability of the
CIITA transcripts in immature and mature DCs (Fig. 6
A). The cells were treated with DRB to block de novo
transcription and CIITA mRNA levels were then deter-
mined at various time points. The half-life of CIITA
mRNA was found to be very short (1 h) in both imma-
ture and mature DCs. No statistically significant difference
in half-life was evident between the two mRNA decay
curves. These results show that the decline in CIITA
mRNA abundance during DC maturation is not due to a
change in mRNA stability.
The fact that the CIITA mRNA decay rate is not modi-
fied during DC maturation implies that the reduction in
CIITA mRNA expression must be due to an arrest in tran-
scription. To confirm this interpretation we measured the
transcription rate of the CIITA gene. A method relying on
the quantification by real time PCR of chromatin-bound
nascent transcripts was employed. This type of approach
represents a sensitive and reliable alternative to the classical
run-on assay (38). In immature DCs, spliced and unspliced
nascent CIITA transcripts derived from pI and pIII are
readily detected (Fig. 6 B). After LPS-induced maturation,
the synthesis of these nascent transcripts is strongly reduced.
Consistently with the steady-state CIITA mRNA measure-
ments (Fig. 3), the reduction is stronger for pI (10- to 20-
fold) than for pIII (5- to 10-fold) (Fig. 6 B). The same ar-
rest in transcription is also revealed by measurements of the
abundance of spliced type I and type III CIITA transcripts
present in the free nuclear RNA fraction (Fig. 6 B). Un-
spliced CIITA transcripts were as expected present at only
very low levels in the free nuclear RNA fraction (data not
shown). This is consistent with the fact that splicing of pre-
cursor transcripts is known to be a cotranscriptional process
that is largely completed before release from the chromatin
template. In conclusion, our findings indicate that the de-
crease in CIITA expression during DC maturation is con-
trolled by transcriptional silencing of the CIITA gene. The
arrest in transcription concerns both pI and pIII of the
MHC2TA gene.
Silencing of the MHC2TA Gene Is Not Accompanied by a
Change in Promoter Occupation. Changes in transcriptional
activity are frequently reflected by alterations in promoter
occupation that can be visualized in living cells by means of
in vivo genomic footprint experiments (39). We used this
technique to study whether silencing of the MHC2TA
gene during DC maturation is accompanied by modifica-
tions in the occupation of pI and pIII. The region situated
immediately upstream of the transcription initiation site of
pI contains a short 120-bp sequence that is highly homolo-
gous between the human and mouse genes. In immature
DCs, the occupation of this proximal region of pI is re-
vealed by the presence of five enhanced guanine residues
on the lower strand and five protected guanine residues on
the upper strand (Fig. 7 A). These enhanced and protected
residues fall within or near sequence motifs representing
potential binding sites for known transcription factors (28;
Fig. 7 A). Surprisingly, no clear changes in this footprint
pattern are detected following the silencing of pI in mature
DC (Fig. 7 A). The proximal region of pI thus remains oc-
cupied despite the reduction in transcription.
The region situated upstream of the transcription initia-
tion site of pIII contains regulatory sequences that are con-
served between the human and mouse genes (28). In im-
mature DCs, the occupation of pIII is characterized by a
footprint pattern that is similar to the one observed in B
cell lines (49; unpublished results). This pattern consists of
(a) a cluster of protections lying within a sequence desig-
nated ARE-1 (a TEF-2–like binding site), (b) a protection
and an enhancement lying within a sequence designated
ARE-2, (c) two protections falling within a sequence des-
ignated site A (an nuclear factor [NF]-1–like binding site),
and (d) a protection in a sequence designated site C (which
resembles an IFN regulatory element; Fig. 7 B). As ob-
Figure 6. The reduction in CIITA expression during DC maturation is
regulated at the level of transcription rather than mRNA stability. (A) Im-
mature DCs and DCs stimulated with LPS for 2.5 h were treated with
DRB for 0, 1, 2, 3, and 4 h. CIITA mRNA abundance was then quanti-
fied by real time PCR. The mean and SEM of three independent experi-
ments are shown. (B) Nascent chromatin-bound transcripts and free nu-
clear RNAs were isolated from immature and mature DCs. Spliced and
nonspliced forms of CIITA type I and type III transcripts were quantified
by real time PCR. Levels of type I and III CIITA transcripts in immature
DCs were set at 100% and are represented by a single bar. The mean and
SEM of two independent experiments are shown.
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served for pI, the footprint pattern of pIII does not change
significantly after maturation of the DCs, indicating that si-
lencing of pIII is not accompanied by an obvious change in
promoter occupation (Fig. 7 B). The similarity in the ob-
servations made for pI and pIII suggests that these two pro-
moters are governed by a common regulatory mechanism
during DC maturation.
An additional protection previously identified in B cells
could not be detected in DCs (49; Fig. 7 B). This protec-
tion falls in a region (site B) representing a putative octamer
sequence, which can be bound by the Oct-1 and Oct-2
transcription factors in association with the B cell specific
coactivator OBF-1 (50). The lack of occupancy of the oc-
tamer site suggests that it is not an essential cis-acting se-
quence for expression of pIII in DCs.
The Entire Regulatory Region of the CIITA Gene Is Deacety-
lated during Maturation. Deacetylation of lysine residues of
the core histone tails is frequently associated with transcrip-
tional repression. Histone deacetylation is thought to result
in a more compact chromatin structure that decreases the
accessibility of chromatin and represses transcription (51–
54). To determine whether histone deacetylation plays a role
in the repression of CIITA transcription during DC matura-
tion, we treated the cells with LPS in the presence of the
deacetylase inhibitor TSA. Administration of TSA inhibited
LPS-induced downregulation of CIITA mRNA (Fig. 8 A).
As expected, this also abolished the downregulation of
MHCII mRNA expression (Fig. 8 A). The finding that si-
lencing of the MHC2TA gene is relieved by TSA suggests
that it is mediated by a mechanism leading to deacetylation
of histones associated with its regulatory region. To deter-
mine whether this is indeed the case, we performed chroma-
tin immunoprecipitation assays with antibodies specific for
acetylated histones. In immature DCs expressing high levels
of CIITA, histone H4, and to a lesser extent histone H3, are
acetylated over the entire 12-kb regulatory region of the
MHC2TA gene (Fig. 8 B). This is evident both within and
outside of the regions containing pI, pIII, and pIV. After
maturation, histone acetylation is lost over the whole regula-
tory region (Fig. 8, B and C). The mechanism driving si-
Figure 7. Extinction of MHC2TA transcription during DC maturation is not accompanied by a change in the occupation of promoters pI and pIII.
The occupation of pI (A) and pIII (B) was analyzed in immature and mature DCs by in vivo genomic footprinting. Results are shown for the upper and
lower strands of pI and for the upper strand of pIII. The first lane in each group shows the pattern obtained in vitro with naked control DNA. The sec-
ond and third lanes in each group show the patterns obtained for immature and mature DCs, respectively. Arrows indicate protected residues. Arrow-
heads indicate enhancements. The bent arrows indicate the sites of transcription initiation. The putative binding motifs are indicated at the left of the gels.
Box 1 is composed of either two NF-IL6 sites or two PEA3 sites. Positions of the protections, enhancements and putative binding sites are indicated on
the sequences of the proximal promoter regions of pI and pIII.
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lencing of the MHC2TA gene thus involves global histone
deacetylation over a large regulatory domain.
Discussion
Precisely orchestrated changes in MHCII expression are
crucial for the ability of DCs to function as professional
APCs. Immature DCs synthesize MHCII molecules at a
high rate but store them in an intracellular compartment
rather than displaying them at the cell surface. When mat-
uration is induced by inflammatory stimuli or infections,
MHCII–peptide complexes are assembled and transported
to the cell surface (4, 5, 10, 11). This increased cell surface
MHCII expression reflects the commitment of DCs to a
state optimized for the presentation of antigenic peptides
to naive CD4 T lymphocytes. In parallel with the in-
crease in cell surface expression, de novo synthesis of
MHCII molecules is actually decreased. This block in syn-
thesis of MHCII molecules ensures that the existing
MHCII–peptide complexes are not replaced or diluted by
new complexes assembled during the maturation and mi-
gration of the DCs. Reduced synthesis of new MHCII
molecules in mature DCs is coherent with the fact that
these cells also loose their capacity for antigen uptake. We
show here that the reduction in de novo MHCII synthesis
occurring during maturation of DCs is due to transcrip-
tional silencing of the gene encoding CIITA, a key regula-
tor of MHCII expression. Two independent promoters, pI
and pIII, of the MHC2TA gene are repressed in a coordi-
nated fashion after exposure to stimuli eliciting DC matu-
ration. This silencing of MHC2TA transcription is remark-
ably rapid. Minimum expression levels are attained after
4 h of stimulation. A wide variety of different maturation
stimuli have the same effect. Finally, the relevance of this
finding is emphasized by the fact that it is observed in hu-
man monocyte-derived DCs, in mouse BMDCs, and in
vivo in splenic DCs in acute Th1-mediated autoimmunity
(EAE).
During an early phase of DC maturation we observed a
transient increase in MHCII mRNA abundance. Elevated
MHCII mRNA levels are evident after 3 h of stimulation
with LPS, but are then reduced to 20–30% of initial levels
by 24–48 h (Fig. 1 C). This initial increase in MHCII
mRNA abundance is consistent with previous metabolic
labeling experiments showing that de novo biosynthesis of
MHCII molecules goes up transiently at early time points
during DC maturation (4). Surprisingly, the transient in-
crease in MHCII mRNA expression is not associated with
elevated CIITA expression and it is thus unlikely to be due
to enhanced transcription of MHCII genes. Instead, it is
tempting to speculate that it could be due to an increase in
the stability of MHCII mRNA. In this respect it should be
mentioned that there is indeed evidence suggesting that
MHCII mRNA stabilization may contribute to the regula-
tion of MHCII expression in other cell types (55, 56).
LPS induces a reduction of CIITA and MHCII expres-
sion in DCs. This contrasts with the effect of LPS in other
types of APCs. For instance, LPS is well known to enhance
constitutive MHCII expression in mouse B cell lines and
primary B cells (57). Human B cells do not respond to LPS
by changing cell surface MHCII expression or DRA
mRNA levels, although we have observed a mild reduc-
tion in CIITA mRNA expression (data not shown). This
reduction is much less rapid and extensive that what is ob-
served in DCs. In human monocytes and macrophages,
two opposing effects have been described: LPS alone has
been shown to stimulate MHCII expression transiently
while it inhibits induction of MHCII expression by IFN-
Figure 8. The entire regulatory region of the MHC2TA gene is
deacetylated during maturation of DCs. (A) Immature DCs were stimu-
lated with LPS in the absence or presence of TSA for 24 h. Total CIITA
and DRA mRNAs were quantified by real time PCR. (B) Chromatin
immunoprecipitation was performed on immature (i) and mature (m)
DCs with antibodies specific for the acetylated histones H3 and H4. Im-
munoprecipitations with preimmune serum (PI) served as a negative con-
trol. The immunoprecipitates were analyzed by PCR for the presence of
seven fragments spanning the entire regulatory region of the MHC2TA
gene (primer pairs A to G). The regulatory region of the MHC2TA gene
and the positions of primer pairs A to G are represented on the left. The
proximal promoter of the GAPDH gene was used as a control. (C) Real
time PCR was performed for quantification of the immunoprecipitated
samples from panel B. Results were normalized with respect to the
GAPDH promoter. For each region (A to G) the value obtained in im-
mature DCs was set at 100%.
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or IL-4 (58, 59). Taken together, these observations indi-
cate that the mechanisms governing modulation of MHCII
expression by LPS must differ between DCs and other
MHCII-positive cell types.
DC maturation can be induced by a variety of infectious
agents and cytokines. We found that downregulation of
CIITA expression is induced by all of the maturation stim-
uli that we tested, indicating that the reduction in CIITA
and MHCII expression is a general consequence of DC
maturation. Although the extinction of CIITA expression
is qualitatively comparable for all stimuli, the efficiency of
this response is variable. Variations between the stimuli are
not unexpected because they use different signaling path-
ways for turning on the DC maturation program. It is re-
markable that all these signal transduction pathways con-
verge on the molecular machinery regulating transcription
of the MHC2TA gene.
We show here that the type I and type III CIITA
mRNAs give rise to three different CIITA proteins having
distinct N-termini. Until now, the existence of three CIITA
protein isoforms had been inferred from the structures of
the different types of CIITA mRNA, but they had not
been formally shown to be synthesized in vivo. Nothing is
known to date about the relative translation efficiencies or
stabilities of the different CIITA protein isoforms, and it is
thus no possible to draw a direct correlation between the
relative abundance of the three CIITA protein isoforms
and the relative abundance of the three types of CIITA
mRNA. In contrast to the rapid disappearance of the 124-
and 132-kD CIITA proteins, the 121-kD protein persists
for a prolonged period of time after the initiation of DC
maturation. Type IV mRNA is not expressed at significant
levels in either immature of mature DCs (see Fig. 3) and is
thus unlikely to account for the persistence of the 121-kD
isoform. Instead, it is likely to be derived from type III CIITA
mRNA (Fig. 2). Continued synthesis of some CIITA pro-
tein is not unexpected because a basal level of type III CIITA
mRNA is retained. However, the explanation for the dif-
ferential rate of disappearance of the isoforms is not clear. It
could be accounted for by differences in the stability of the
isoforms. Persistence of the 121-kD isoform is likely to be
responsible for the residual (20%) level of MHCII gene
transcription that is retained in mature DCs after 24 to 48 h
of stimulation.
Our genomic footprint experiments have pinpointed a
number of sites in pI and pIII that are occupied in vivo in
DCs. This represents a strong indication that these se-
quences constitute important cis-acting regulatory elements
for the activity of pI and pIII in DCs. Confirmation of this,
and identification of the relevant transcription factors that
bind to these sequences, will require further work. These
studies will not be trivial because they are severely ham-
pered by the necessity of working with primary DCs,
which are difficult to obtain in large numbers and to trans-
fect. Stable DC cell lines have been established (60–63).
However, these cell lines are not suitable because in our
hands they either do not express significant levels of CIITA
and MHCII, or do not respond to maturation stimuli in a
manner that is identical to that observed for primary DCs
(unpublished data).
In mature DCs, pI and pIII remain occupied despite the
fact that they are transcriptionally silent. This is similar to
the situation observed in plasmocytes, in which silencing of
CIITA expression is also accompanied by continuous pIII
occupation (unpublished data). On the other hand it con-
trasts with observations made in other cell types in which
these promoters are not active. For instance, pI is bare in B
cells, and neither pI nor pIII are occupied in IFN- stimu-
lated fibroblasts (unpublished data).
The type I and type III CIITA mRNAs are lost coordi-
nately and with similar kinetics in LPS-stimulated human
monocyte-derived DCs. This reduction is due to a coordi-
nate silencing of the two promoters, pI and pIII, that drive
transcription of the MHC2TA gene. The three different
forms of CIITA mRNA are also reduced coordinately in
mouse BMDCs treated with LPS. These findings are rather
surprising because the different CIITA promoters are dis-
tributed over more than 12 kb of DNA, do not share any
sequence homology, and are known to be regulated inde-
pendently in cell types other than DCs. Taken together,
these results suggest that silencing during DC maturation is
mediated by a higher order regulatory mechanism affecting
all MHC2TA promoters simultaneously. We show here that
this mechanism involves global histone deacetylation over a
large 12-kb region encompassing the entire regulatory re-
gion of the MHC2TA gene. Silencing of the MHC2TA
gene during DC maturation thus appears to be mediated by
chromatin remodeling of a large domain rather than by lo-
calized repression restricted to individual promoters.
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